Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang
{"title":"雷马唑仑联合艾氯胺酮对门诊手术患者麻醉疗效和精神症状的影响:一项随机对照研究。","authors":"Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang","doi":"10.2147/DDDT.S519732","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.</p><p><strong>Results: </strong>Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (<i>p</i><0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (<i>p</i><0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (<i>p</i><0.05). Groups E and ER displayed a shorter extubation time than Group EM (<i>p</i><0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (<i>p</i><0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4527-4535"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132051/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.\",\"authors\":\"Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang\",\"doi\":\"10.2147/DDDT.S519732\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.</p><p><strong>Results: </strong>Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (<i>p</i><0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (<i>p</i><0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (<i>p</i><0.05). Groups E and ER displayed a shorter extubation time than Group EM (<i>p</i><0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (<i>p</i><0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"4527-4535\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132051/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S519732\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S519732","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.
Background: The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.
Methods: A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.
Results: Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (p<0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (p<0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (p<0.05). Groups E and ER displayed a shorter extubation time than Group EM (p<0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (p<0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (p<0.05).
Conclusion: The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.